QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:ARGX

argenx (ARGX) Stock Forecast, Price & News

$491.63
+5.67 (+1.17%)
(As of 04:31 PM ET)
Compare
Today's Range
$485.55
$496.14
50-Day Range
$477.79
$548.43
52-Week Range
$333.07
$550.76
Volume
272,427 shs
Average Volume
250,441 shs
Market Capitalization
$28.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$519.55

argenx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
5.4% Upside
$519.55 Price Target
Short Interest
Healthy
1.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of argenx in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.10) to ($3.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

620th out of 972 stocks

Biological Products, Except Diagnostic Industry

92nd out of 158 stocks


ARGX stock logo

About argenx (NASDAQ:ARGX) Stock

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Price History

ARGX Stock News Headlines

Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
argenx's (ARGX) Buy Rating Reiterated at HC Wainwright
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
What 20 Analyst Ratings Have To Say About argenx
argenx SE
Is Argenx Stock a Buy Now?
Stifel Nicolaus Reaffirms Their Buy Rating on Argenx Se (ARGX)
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Company Calendar

Last Earnings
7/27/2023
Today
9/29/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
843
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$519.55
High Stock Price Forecast
$609.00
Low Stock Price Forecast
$246.00
Forecasted Upside/Downside
+5.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
21 Analysts

Profitability

Net Income
$-709,590,000.00
Pretax Margin
-52.69%

Debt

Sales & Book Value

Annual Sales
$445.27 million
Book Value
$50.79 per share

Miscellaneous

Free Float
57,115,000
Market Cap
$28.86 billion
Optionable
Optionable
Beta
0.75
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 51)
    M.B.A., M.Sc., MSc, CEO & Exec. Director
    Comp: $1.44M
  • Mr. Karl Gubitz (Age 53)
    Chief Financial Officer
  • Ms. Malini Moorthy (Age 53)
    Gen. Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 38)
    VP of Corp. Devel. & Strategy
  • Ms. Andria Wilk (Age 49)
    Global Head of Quality
  • Mr. Luc Truyen (Age 58)
    Chief Medical Officer
  • Ms. Karen Massey (Age 44)
    Chief Operating Officer
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 43)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corp. Communications & Investor Relations













ARGX Stock - Frequently Asked Questions

Should I buy or sell argenx stock right now?

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 sell rating, 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price forecast for 2023?

21 analysts have issued 12 month price objectives for argenx's shares. Their ARGX share price forecasts range from $246.00 to $609.00. On average, they expect the company's share price to reach $519.55 in the next year. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2023?

argenx's stock was trading at $378.83 on January 1st, 2023. Since then, ARGX shares have increased by 30.1% and is now trading at $493.00.
View the best growth stocks for 2023 here
.

Are investors shorting argenx?

argenx saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 655,800 shares, a decline of 6.5% from the August 31st total of 701,500 shares. Based on an average daily volume of 302,700 shares, the short-interest ratio is presently 2.2 days.
View argenx's Short Interest
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings results on Thursday, July, 27th. The company reported ($1.69) EPS for the quarter, meeting analysts' consensus estimates of ($1.69). The company earned $281.16 million during the quarter, compared to the consensus estimate of $258.32 million. argenx had a negative net margin of 47.28% and a negative trailing twelve-month return on equity of 27.99%. During the same period in the previous year, the company earned ($3.81) EPS.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $493.00.

How much money does argenx make?

argenx (NASDAQ:ARGX) has a market capitalization of $28.86 billion and generates $445.27 million in revenue each year. The company earns $-709,590,000.00 in net income (profit) each year or ($7.17) on an earnings per share basis.

How many employees does argenx have?

The company employs 843 workers across the globe.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -